The dosing convenience afforded by Cidara Therapeutics, Inc.’ rezafungin warrants the antifungal’s approval for treatment of candidemia/invasive candidiasis in adults with limited or no alternative treatment options, members of a US Food and Drug Administration advisory committee said on 24 January.
The Antimicrobial Drugs Advisory Committee voted 14-1 that rezafungin’s benefit-risk assessment is favorable in a limited use indication and would...





